Kinfo
Inmune Bio Inc. logo

Inmune Bio Inc.

INMBNASDAQHealthcare·US · USD
$1.63
+0.21 (+14.79%)
Live · 2026-06-29

Price

Key statistics

Valuation
Market cap37.75M USD
Enterprise value17.90M USD
Trailing P/E-0.88
Forward P/E-2.70
PEG ratio0.02
Price / sales755.02
Price / book1.92
Profitability
Gross margin0.00%
Operating margin-61738.00%
Profit margin0.00%
Return on assets-52.61%
Return on equity-168.78%
Income (TTM)
Revenue50.00K USD
Gross profit0.00 USD
EBITDA0.00 USD
Net income-41.60M USD
Diluted EPS-$1.63
Rev. growth (YoY)0.00%
Balance sheet
Total cash21.36M USD
Total debt1.51M USD
Debt / equity7.70
Current ratio4.24
Book value / share$0.74
Cash flow (TTM)
Operating cash flow-19.16M USD
Levered free cash flow-11.25M USD
Shares & price
Shares outstanding26.59M
Float22.16M
Held by institutions19.69%
Beta1.01
50-day MA$1.40
200-day MA$1.57
52-week high$3.24
52-week low$1.09
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-07-0.18-0.20−11.11%2026-03-27-3.78-0.97+74.34%2025-10-30-0.32-0.24+25.00%
About Inmune Bio Inc.

Inmune Bio Inc. is a biotechnology company focused on the development of innovative therapies for modulating the immune system. The primary purpose of its research and development efforts is to create treatments that help in managing and potentially curing a range of conditions by targeting innate immune functions. This approach is significant in the medical field, particularly in autoimmune diseases, cancer, and neurodegenerative disorders, where the immune system's regulation can have profound impacts on disease progression and patient outcomes. By harnessing the body's own defense mechanisms, Inmune Bio Inc. aims to advance therapeutic solutions that are both effective and minimize adverse side effects. Operating in a rapidly evolving sector, the company holds an influential role in the biotechnology market, contributing to cutting-edge scientific advancements. By fostering collaborations with research institutions and leveraging its proprietary technologies, Inmune Bio Inc. continues to push the boundaries of immune-based treatments, offering hope for novel applications across different medical conditions.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. David J. Moss M.B.A.
Employees
21
Headquarters
Boca Raton, FL, United States

Frequently asked questions about Inmune Bio Inc.